prediction
HanAll Biopharma is forecast to post 2027 revenue of 177.3 billion KRW, operating profit of 10.6 billion KRW, and an operating margin of 6.0%.
A prediction by report author. Statements are as reported by the cited publishers — not verified by DecisionGateway.
2027년 매출 177.3십억원 / 영업이익 10.6십억원 / 영업이익률 6.0%
Related claims
HanAll Biopharma is forecast to post 2026 revenue of 169.3 billion KRW, operating profit of 12.0 billion KRW, and an operating margin of 7.1%.report author · predictionRFHIC's financial forecasts are: 2025 revenue 185.8 billion won, operating profit 30.9 billion won, operating margin 16.6%; 2026 revenue 262.1 billion won, operating profit 62.7 billion won, operating margin 23.9%; 2027 revenue 318.0 billion won, operating profit 75.3 billion won, operating margin 23.7%.report author · prediction2026 consolidated revenue is forecast at 4.5459 trillion KRW and operating profit at 1.263 trillion KRW.하나증권 · prediction2027년 매출 4조 7,902억원, 영업이익 1조 3,268억원, 영업이익률 27.7%를 기록할 것으로 전망된다.리포트 작성자(증권사) · prediction2027년 매출 7,620.6십억원 / 영업이익 900.0십억원 / 영업이익률 11.8%를 기록할 것으로 전망된다.리포트 작성자 · prediction2027년 매출 13,481.2억원, 영업이익 514.8억원, 영업이익률 3.8%를 기록할 것으로 전망된다.리포트 작성자 · prediction